AQR Capital Management
SNDX icon

AQR Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

AQR Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.9M Buy
980,314
+54,340
+6% +$1.18M 0.01% 986
2025
Q4 		$19.5M Buy
925,974
+367,898
+66% +$6.42M 0.01% 944
2025
Q3 		$8.59M Buy
558,076
+327,499
+142% +$4.29M 0.01% 1172
2025
Q2 		$2.16M Sell
230,577
-146,867
-39% -$1.62M ﹤0.01% 1728
2025
Q1 		$4.64M Buy
377,444
+312,231
+479% +$4.4M ﹤0.01% 1159
2024
Q4 		$862K Buy
65,213
+39,794
+157% +$681K ﹤0.01% 1964
2024
Q3 		$489K Sell
25,419
-1,854
-7% -$38.3K ﹤0.01% 2178
2024
Q2 		$560K Sell
27,273
-25,943
-49% -$543K ﹤0.01% 2007
2024
Q1 		$1.27M Buy
53,216
+17,314
+48% +$386K ﹤0.01% 1596
2023
Q4 		$776K Buy
35,902
+11,330
+46% +$174K ﹤0.01% 1699
2023
Q3 		$357K Buy
24,572
+3,034
+14% +$57.4K ﹤0.01% 1967
2023
Q2 		$451K Sell
21,538
-1,690
-7% -$35.2K ﹤0.01% 1821
2023
Q1 		$491K Sell
23,228
-1,947
-8% -$48.4K ﹤0.01% 1782
2022
Q4 		$641K Buy
25,175
+3,246
+15% +$75.7K ﹤0.01% 1722
2022
Q3 		$527K Sell
21,929
-13,429
-38% -$301K ﹤0.01% 1759
2022
Q2 		$680K Buy
35,358
+11,607
+49% +$193K ﹤0.01% 1570
2022
Q1 		$413K Buy
+23,751
New +$400K ﹤0.01% 1884
2021
Q2 		– Sell
-18,680
Closed -$418K – 2291
2021
Q1 		$418K Sell
18,680
-11,283
-38% -$255K ﹤0.01% 1901
2020
Q4 		$666K Sell
29,963
-12,972
-30% -$269K ﹤0.01% 1682
2020
Q3 		$634K Sell
42,935
-1,873
-4% -$28.6K ﹤0.01% 1634
2020
Q2 		$664K Buy
44,808
+34,079
+318% +$519K ﹤0.01% 1648
2020
Q1 		$118K Buy
+10,729
New +$101K ﹤0.01% 1949
2019
Q2 		– Sell
-14,117
Closed -$74K – 2175
2019
Q1 		$74K Buy
+14,117
New +$80.5K ﹤0.01% 2146
2018
Q1 		– Sell
-26,068
Closed -$228K – 2272
2017
Q4 		$228K Sell
26,068
-7,121
-21% -$70.5K ﹤0.01% 2123
2017
Q3 		$388K Buy
+33,189
New +$407K ﹤0.01% 2013

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

AQR Capital Management's SNDX Position: Q1 2026 in Review

AQR Capital Management increased its Syndax Pharmaceuticals (SNDX) stake by 5.9% in Q1 2026, buying an estimated $1.18M and bringing the position to 980,314 shares worth $22.9M. The position accounts for 0.01% of the portfolio, ranked #986.

AQR Capital Management first reported a position in SNDX in Q3 2017 and has held it in 25 quarters since. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • AQR Capital Management held 980,314 shares of Syndax Pharmaceuticals worth $22.9M as of Q1 2026.
  • AQR Capital Management bought 54,340 Syndax Pharmaceuticals shares in Q1 2026, an estimated $1.18M.
  • Syndax Pharmaceuticals made up 0.01% of AQR Capital Management's portfolio in Q1 2026, its #986 holding.
  • AQR Capital Management first reported a position in Syndax Pharmaceuticals in Q3 2017 and has held it in 25 quarters since.
  • 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.